- You can view the full Pharmasset Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Idenix shares surge as the concerns about the safety of its hepatitis C drug appear to be lifted.
The arms race to develop the next generation of hepatitis C therapies is escalating.
Investors are nervous about the safety of Inhibitex's hepatitis C drug ahead of an important safety check.